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ABSTRACT
Background  and  aim  :  Whole-body  (18)fluor-deoxyglucose  positron  emission 
tomography/computed tomography (PET/CT) has emerged as a promising diagnostic 
modality  in  different  tumors.  The  role  and  the  utility  of  (18)FDG-PET/CT  in 
resectable  pancreatic  cancer  is  debated.  Aim  of  the  present  work  was  to  assess 
prospectively the value of (18)FDG-PET/CT in addition to conventional imaging as a  
staging modality in candidates for resection of resectable pancreatic cancer. Secondary 
aim is to correlate (18)FDG-PET/CT results with tumor-recurrence after resection.
Material and methods : Whole-body (18)FDG-PET/CT was performed in 72 patients 
with pancreatic ductal adenocarcinoma who were judged resectable at high-resolution 
imaging.  Neoadjuvant  therapy  was  performed  in  the  14%  of  cases.  Maximum 
standardized uptake value (SUVmax) was evaluated 60 minutes after FDG injection. 
PET/TC was considered "positive" for pancreatic cancer when SUV > 3.
Results  :  8/72 (11%) patients  were  spared  unwarranted  resection  since  (18)FDG-
PET/CT  detected  synchronous  advanced  lung  cancer  (n=1)  or  metastatic  disease 
(n=7). Median CA 19.9 was 48.8 U/mL for the entire cohort and 292 U/mL for seven  
patients with metastases (p=0.112). In other two patients (18)FDG-PET/CT identified 
one  colon  carcinoma  and  a  thoracic  neurinoma.  15/72  (21%)  patients  had  low 
metabolic  activity  (SUVmax<3),  and  60%  of  these  patients  had  undergone 
neoadjuvant treatment (p=0.0001). At laparotomy 3/64 (5%) patients did not undergo 
resection because of locally-advanced (n=1) or metastatic disease (n=2). 61 patients 
underwent pancreatic resections with curative intent. N1 rate was 77%, with a median 
of 33 resected nodes. In 8/61 (13%) patients (18)FDG-PET/CT identified metastatic 
lymph  nodes  that  required  an  extension  of  lymphadenectomy.  Sensitivity  and 
specificity of (18)FDG-PET/CT for the detection of metastatic disease were 78% and 
100%, respectively. Median follow-up for resected patients was 10 months and 53% 
of them developed recurrence. No significant correlation between SUVmax values and 
disease-free survival was found.
Conclusions  :  (18)FDG-PET/CT  findings  resulted  in  changes  of  therapeutic 
management/operative  procedures  in  one  third  of  patients.  (18)FDG-PET/CT 
improves staging of patients with resectable pancreatic cancer. Neoadjuvant treatment 
is significantly associated with low metabolic activity limiting the value of (18)FDG-
PET/CT in this setting. 
ABSTRACT
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Introduzione  e  obiettivi  :  La  PET/TC con  18-fluoro-desossiglucosio  -  (18)FDG-
PET/CT  -  si  è  affermata  come  una  promettente  tecnica  diagnostica  in  diverse  
neoplasie.  L’utilità  della  (18)FDG-PET/CT nel  carcinoma pancreatico  resecabile  è 
dibattuto. Obiettivo di questo studio è di valutare in maniera prospettica il ruolo della 
(18)FDG-PET/CT in aggiunta all’imaging convenzionale per lo staging di  pazienti  
candidati a resezione pancreatica per carcinoma. Obiettivo secondario è valutare una 
possibile correlazione tra (18)FDG-PET/CT e ricorrenza di malattia dopo resezione.
Materiali  e  metodi  :  (18)FDG-PET/CT  è  stata  effettuata  in  72  pazienti  con 
adenocarcinoma pancreatico considerate resecabile all’imaging ad alta risoluzione. La 
terapia  neoadiuvante  è stata effettuata nel  14% dei  casi.  Il  maximum standardized 
uptake value (SUVmax) è stato valutato 60 minuti dopo la somministrazione di FDG. 
La PET/TC è considerata "positiva" per carcinoma se SUV > 3.
Risultati :  8/72 (11%) pazienti non sono stati sottoposti a intervento chirurgico per 
l’evidenza  di   malattia  metastatica  (n=7)  e  di  un  carcinoma  polmonare  avanzato 
sincrono (n=1) alla  (18)FDG-PET/CT. Il valore mediano di Ca 19.9 è stato di 48.8 
U/mL per l’intera coorte e di 292 U/mL per i pazienti metastatici (p=0.112). In altri  
due pazienti la (18)FDG-PET/CT ha identificato un carcinoma colico e un neurinoma 
mediastinico.  15/72  (21%)  pazienti  avevano  un  SUVmax<3,  e  il  60%  di  questi 
pazienti  era stato sottoposto a terapia neoadiuvante (p=0.0001).  3/64 (5%) pazienti 
non sono stati resecati per malattia avanzata alla laparotomia. Il 77% dei 61 pazienti 
resecati presentava metastasi linfonodali. Nel 13% dei casi la (18)FDG-PET/CT ha 
identificato  metastasi  linfonodali  che  hanno  richiesto  una  estensione  della 
linfoadenectomia. Sensibilità e specificità della PET/CT per malattia metastatica sono 
state del 78%e 100%. Il follow-up mediano dei pazienti resecati è stato di 10 mesi e il  
55% di essi ha sviluppato una recidiva. Non è stata identificata alcuna correlazione 
significativa tra SUVmax e sopravvivenza libera da malattia.
Conclusioni : La PET/CT ha determinate un cambiamento nella strategia terapeutica 
del 25% dei pazienti, migliorando lo staging preoperatorio dei pazienti con carcinoma 
pancreatico candidati alla resezione chirurgica. Il trattamento neoadiuvante si associa  
ad una riduzione significativa dei  valori  di  SUV, limitando pertanto il  ruolo della 
PET/CT in questi pazienti.
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INTRODUCTION
Although the diagnosis and management of pancreatic cancer has improved in the last 
decades, its prognosis remains dismal. Surgical resection is the only treatment with 
potentially curative intent with a 5-year survival rate of 20-25% [1-4]. Moreover, 20 to 
30% of resected patients will develop tumor-recurrence and die of disease within 12 
months from resection [5]. These deaths can be related to tumors with an aggressive 
biological behavior with unrecognized or rapidly progressive metastatic disease [6,7].  
If this subgroup of patients could be identified in the preoperative setting, neoadjuvant  
chemotherapy should be considered instead of upfront surgery [2,6].
Therefore, detection of distant metastases and identification of aggressive tumors at 
diagnosis  is  of  paramount  importance  when  deciding  if  an  operation  should  be 
performed for pancreatic carcinoma. Despite significant advances of high-resolution 
imaging techniques, the appropriate assessment of resecability of pancreatic cancer is 
still  challenging  [8-11].  Particularly,  the  diagnosis  of  small  metastases  can  be 
problematic  even  in  the  setting  of  contrast-enhanced,  multi-detector  computed 
tomography (MDCT) [12,13].
Whole body 2-(fluorine-18)fluoro-deoxy-D-glucose-positron emission tomography in 
combination with computed tomography (FDG-PET/CT) has emerged as a promising 
imaging modality in the management of cancer patients [14].  (18)F-FDG PET can 
image tumoral cells thanks to their accelerated glucose metabolism. These functional  
information are then combined with the anatomical details of CT scan. (18)F-FDG 
PET/CT has demonstrated significant efficacy in the staging and detection of occult 
metastases  in  a  number  of  malignancies,  including  oesophagogastric  carcinomas, 
small and non-small cell lung cancer (NSCLC), breast cancer and lymphoma [15-19].  
Furthermore, (18)F-FDG PET/CT has been identified as a prognostic factor for tumor 
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recurrence after surgery in gastric cancer, NSCLC and gynaecological cancers [20-
22].
The  role  of  (18)F-FDG PET/CT in  patients  with  potentially  resectable  pancreatic 
cancer  is  still  debated.  In  this  setting,  while  some  authors  have  reported  a  high 
sensitivity rate for identifying occult  metastatic disease [12,23-25] ,  others did not  
favor PET/CT over MDCT for properly staging pancreatic cancer [26,27]. Moreover, 
few studies have evaluated if  (18)F-FDG PET/CT could be a prognostic indicator of  
tumor-recurrence and survival after resection of pancreatic cancer [28,29].
The primary end point of the present study was to prospectively evaluate the role of 
(18)F-FDG PET/CT  for  detecting  occult  metastatic  disease  and  its  impact  on  the 
management of patients with resectable pancreatic cancer after conventional staging 
based on high-resolution imaging techniques. Secondary end points included i) assess 
the accuracy of (18)F-FDG PET/CT in the identification of lymph node metastases; ii) 
evaluate a possible prognostic role of (18)F-FDG PET/CT for tumor-recurrence in 
patients undergoing pancreatic resection.
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MATERIALS AND METHODS
The study population  was  represented  by  all  consecutive  patients  with  potentially 
resectable pancreatic ductal adenocarcinoma who prospectively underwent (18)F-FDG 
PET/CT at Ospedale Sacro Cuore-Don Calabria, Negrar, Italy between May 2011 and 
July 2012
Preoperative  staging  and  surgical  resectability  were  based  on  abdominal  MDCT 
and/or  magnetic  resonance  imaging  (MRI)  and  chest  X-ray.  Chest  CT  scan  and 
pancreatic endoscopic ultrasound (EUS) were performed on selected cases. MDCT or 
MRI performed outside our Hospital were reviewed by a multidisciplinary team to 
assess the quality of these examinations. In doubtful situation, preoperative staging 
was performed at our hospital and it was based on contrast-enhanced, multi-detector 
(2.5 mm slice thickness) abdominal computed tomography with pancreas protocol.
The preoperative radiological diagnosis of potentially resectable pancreatic cancer was 
based on the following criteria: 1) absence of abutment/encasement of portal vein, 
superior mesenteric vein, hepatic artery, superior mesenteric artery, celiac trunk; 2)  
absence of infiltration of peripancreatic organs with the exception of common bile 
duct and duodenum; 3) absence of distant metastases.
Exclusion criteria included: 1) age less than 18 years; 2) presence of locally-advanced 
or metastatic pancreatic cancer; 3) presence of poor general conditions or of severe  
comorbidities  that  precluded  patients  from  undergoing  surgery;  4)   patients  with 
pancreatic  tumors  other  than  ductal  adenocarcinoma  (i.e.  intraductal  papillary 
mucinous neoplasms). Patients with an initial diagnosis of “borderline-resectable” or 
locally-advanced pancreatic cancer who underwent neoadjuvant  treatment and who 
showed  tumor-downstaging  to  potentially  resectable  disease  were  included  in  the 
study.  
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All  patients  underwent  (18)F-FDG  PET/CT  two  or  three  day  before  the  planned 
admission to the Hospital.  They were asked to fast  for at least  6 hours before the  
examination.  The  blood  glucose  level  of  each  patient  was  determined  before  the  
examination. Scanning of patients with diabetes mellitus was not performed until the  
blood glucose level was less than 140 mg/dL.  All examinations were carried out by a 
single,  highly  experienced,  nuclear  medicine  physician  (MS).   All  the  tests  were 
performed using a hybrid PET/CT scanner (Siemens mCT Biograph, Germany). The 
whole-body CT scanning was performed using a continuous spiral technique on a 64-
slice helical CT, and the PET scanner had three detector rings. No contrast medium 
was  administered  during  CT  scanning.  After  CT  scan,  an  emission  scan  was 
performed from the head to the thigh after the intravenous injection of 0.08 mC/kg 
(2.96 MBq/kg) FDG. PET scanning is performed with a 16 cm bed for about 7/8 bed  
per patient. CT and PET scan data were co-registered. The standardized uptake value 
(SUV) was acquired using the attenuation-corrected images, the amount of injected 
FDG, the body weight of the patient, and the cross-calibration factors between PET 
and the dose calibrator. Maximum SUV (SUVmax) was evaluated 60 minutes after 
FDG injection and a value of SUVmax of more than 3 being indicative of malignancy. 
Medium 
Patients’ demographics, clinical presentation, serum carbohydrate antigen (CA 19.9) 
levels, operative and postoperative data, complications, pathology and follow-up data 
were  prospectively  collected.  Formal  pancreatic  resections  were  carried  out  if 
intraoperative  exploration  confirmed  1)  the  absence  of  metastatic  disease;  2)  no 
involvement  of  celiac  trunk,  hepatic  artery  or  superior  mesenteric  artery;  3)  no 
involvement of portal vein/superior mesenteric vein or encasement < 180° of these  
vessels. Standard lymphadenectomy was commonly performed as described elsewhere 
[30].
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Classification  of  pancreatic  ductal  adenocarcinoma  was  based  on  the  WHO 2010 
classification of digestive tumors [31]. Quality of resection was determined according 
to the R-classification by the International Union Against Cancer. Tumor (T), nodal 
status  (N)  and grade  (G)  were  determined  using  standard  TNM classification 
according to AJCC classification [32].  Histopathologic grading of pancreatic ductal 
adenocarcinoma  included [31]: (1)  G1,  well-differentiated  neoplasms;  (2)  G2, 
moderately  differentiated  neoplasms;  (3)  G3, poorly  differentiated  neoplasms. 
Intraoperative evaluation of the resection margins was performed routinely, and when 
positive, the resection was extended whenever possible.
Adjuvant treatment was considered in all patients who experienced a good recovery 
within 8 weeks from operation. 
The follow-up schedule was described elsewhere [5].  Recurrence was defined as the 
presence  of  locoregional  disease  (ie,  recurrence  in  the  pancreatic  remnant, 
peripancreatic tissue, or lymph nodes metastases) or of metastatic disease (ie, liver 
metastases,  peritoneal  carcinomatosis)  by  radiologic  imaging  techniques.  Tumor 
recurrence was confirmed histologically whenever possible. Follow-up was updated 
on February 2013.
Statistical analysis 
Distributions of continuous variables are reported as median and minimum/maximum 
range.  Categorical variables  are  presented  as  numbers  and  percentages. The 
comparison  between  subgroups  was performed  with  the  Student  t  test  or  Mann-
Whitney U test for continuous variables. Qualitative data were compared by the χ² 
test or Fisher exact test when necessary. Disease-free survival (DFS) was defined as 
the time from resection to tumor-recurrence and was censored at the last follow-up 
date  if  no  events  had  occurred.  Patients  who  eventually  died  of  postoperative 
complications were excluded from survival analysis. Cut-off points were calculated 
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around  the  median  for  continuous  variables.  Survival probability  was  estimated 
according to the Kaplan-Meier method. Statistical analyses were performed in SPSS 
16.0  for  Windows software  (SPSS  Inc,  Chicago,  IL).  P  values were  considered 
significant when less or equal than .05.
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RESULTS
Seventy-two consecutive patients were prospectively included in the study. The main 
patient characteristics are reported in Table 1
Table 1. Patient characteristics.
N %
Sex
               Male
               Female
72
36
36
50
50
Median age, years (range) 65 39-81
Symptomatic patients
Presence of diabetes
64
15
89
21
Symptoms
               Jaundice
               Weight loss
               Pain
               Bowel obstruction
               Pancreatitis
Tumoral markers
               CEA, ng/ml, median (range)
               CA19-9, U/ml, median (range)
Neoadjuvant treatment
               Chemotherapy
               Chemoradiation
47
32
30
4
1
1.80
64.4
14
7
7
65
44.5
41.5
5.5
1.5
0.5-19.9
0.8- 3547
19
9.5
9.5
Fourteen  patients  (19%)  underwent  neoadjuvant  treatment  because  of  locally-
advanced (n=7) or borderline resectable pancreatic cancer (n=7). In all these patients,  
re-staging after neoadjuvant therapy showed the presence of a potentially resectable 
disease.
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SUVmax < 3 was found in 15 patients (21%) while in the 79% of patients (18)F-FDG 
PET/CT  was  positive  for  malignancy  (SUVmax  >3).  The  60%  of  patients  with 
SUVmax < 3 had undergone neoadjuvant treatment compared to a rate of neoadjuvant 
therapy of 10.5% in the group with SUVmax > 3 (P= 0.0001). Median SUVmax value 
was 5.9 (range 2.5-24.5) in the entire cohort and 6.7 (range 2.5-24.5) in all patients but 
those who underwent neoadjuvant therapy.
Figure 1 shows the results of (18)F-FDG PET/CT with patients management. Eight 
out  of  72  patients  (11%)  were  spared  surgical  resection  because  of  (18)F-FDG 
PET/CT findings. In seven patients occult distant metastases were found, and they 
were histologically/cytologically confirmed after fine-needle aspiration. 
Figure 1. Flow chart showing the results of (18)F-FDG PET/CT with patients management
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In the remaining patient (18)F-FDG PET/CT showed the presence of a synchronous 
NSCLC with mediastinal lymph node metastases. In patients with occult metastatic 
disease, median CA 19.9 value was 292 U/ml  (range 47- 3547) compared to 48.8 
U/mL (range 10-256) of the remaining patients (P= 0.112).
Sensitivity and specificity of (18)F-FDG PET/CT for the detection of occult metastatic  
disease  in  the  entire  cohort  of  72  patients  were  78%  and  100%,  respectively.  
Sensitivity and specificity were 87.5% and 100%, respectively, excluding those 14 
patient who underwent neoadjuvant treatment, as SUVmax was < 3 in 2/3 of these 
patients.
Exploratory laparotomy was planned in 64 patients (89%). In two of them, (18)-F-
FDG PET/CT confirmed the presence of a pancreatic head cancer and showed the 
presence of an associated extrapancreatic synchronous tumor, in the left colon and in 
the posterior mediastinum, respectively. The first patient underwent colonoscopy with 
biopsy  that  confirmed  the  presence  of  a  colonic  carcinoma.  The  second  patient 
underwent  thoracoscopy  with  resection  of  a  mediastinal  neurinoma.  Both  patients 
subsequently underwent pancreaticoduodenectomy, associated with left colectomy in 
the first patient.
A  pancreatic  resection  was  carried  out  in  61/64  (95%)  patients  who  underwent 
laparotomy.  The remaining  three patients (Figure 1) did not undergo pancreatectomy 
because of unresectable locally-advanced (n=1) and a metastatic disease (n=2). The 
two patients with intraoperative evidence of metastatic disease had a SUVmax < 3. In 
one of these two cases laparotomy was carried out after neoadjuvant chemoradiation 
for a locally-advanced tumor of the pancreatic tail  with radiological  down-staging.  
Table 2 shows operative procedures and postoperative complications. In keeping with 
anatomic  location,  pancreaticoduodenectomy  was  the  most  common  surgical 
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procedures  (80%).  There  was  one  postoperative  death  (1.5%)  due  to  sepsis  after 
pancreatic fistula with intra-abdominal abscess and late bleeding.
Table 2. Operative procedures and postoperative complications
N %
Pancreatic resection
    Pancreaticoduodenectomy     
    Left pancreatectomy and 
splenectomy
    Total pancreatectomy
    Vascular resection
Postoperative mortality
Overall morbidity
     Pancreatic fistula
     Abdominal collection
     Sepsis
     DGE
     Bleeding
     Chilous fistola
    
49
7
5
14
1
28
11
10
7
6
5
4
80
 12
8
23
1.5
46
18
16
11.5
10
8
6.5
Pathological  data are reported in Table 3.  The histological  diagnosis of  pancreatic 
ductal adenocarcinoma was confirmed in all 61 patients who underwent resection. The 
patient  who  underwent  colonic  resection  had  a  T3N1  colonic  adenocarcinoma 
associated with pancreatic cancer.50% of patients had a G3 tumor, and lymph node 
metastases were found in 77% of the cases. There was no any significant correlation 
between SUVmax values and any of the following pathological parameters: grading, 
tumor size, nodal status, R status, presence of perineural or microvascular invasion.
(18)F-FDG PET/CT showed an increased FDG uptake in the abdominal lymph nodes 
in 11/61 patients (18%) who underwent surgical resection. Particularly, (18)F-FDG 
PET/CT identified in 8/11 patients suspected nodal metastases in lymph node stations 
outside the area of standard lymphadenectomy. Therefore in these eight patients an 
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extension of lymphadenectomy was required, and lymph nodes along celiac trunk and 
superior mesenteric artery and around the abdominal aorta (para-aortic nodes) were 
removed.  Final  histological  examination  showed  the  presence  of  lymph  node 
metastases in 10/11 patients with PET/CT findings of nodal metastases, and in 7/8 
patients who required an extension of lymphadenectomy.
Table 3. Pathology data in 61 patients who underwent pancreatic resection
N %
Median tumor size (mm), range
Grading
                    G1
                    G2
                    G3
Microvascular invasion
Perineural invasion
R status
                    R0
                    R1
                    R2
T stage
                    T1
                    T2
                    T3
N status
                    N0
                    N1
25
0
31
30
57
55
52
9
0
1
1
59
14
47
8-50
0
51
49
93
90
85
15
0
1.5
1.5
97
23
77
Sensitivity and specificity of (18)F-FDG PET/CT for detecting lymph node metastases 
in 61 resected patients were 21% and 93%, respectively. Median number of resected 
nodes in patients who underwent standard lymphadenectomy was 32 (range 10-52) 
compared to 44 (range 28-91) nodes when an extended lymphadenectomy was carried 
out (P=0.235).
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(18)F-FDG  PET/CT  modified  the  clinical  and  therapeutic  management  of  18/72 
patients  (25%)  who  were  deemed  to  undergo  pancreatic  resection  for  resectable 
pancreatic cancer. (18)F-FDG PET/CT diagnosed advanced disease in eight patients 
(11%), identified synchronous, extra-pancreatic,  resectable tumors in two (3%), and 
identified  another  eight  patients  (11%)  who  required  an  extension  of 
lymphadenectomy. Excluding patients who underwent neoadjuvant treatment (n=14), 
(18)F-FDG PET/CT changed the management of 18/58 patients (31%).
Median follow-up for resected patients was 10 months (range 4-20).  53% of them 
developed  tumor  recurrence.  Of  these  patients,  24  (75%)  had  distant  metastases 
whereas 8 (25%) loco-regional recurrence. Twelve patients died of disease. Median 
disease-free survival was 12 months (Figure 2). The 6-month and 1-year DFS for all 
resected  patients  were  80% and  49% respectively.  Median  SUVmax was  3.25  in 
patients without recurrence versus 3.4 in those with recurrence (P=NS). Considering 
all resected patients, median DFS was 10 months for those with SUVmax>6 and it 
was not reached for patients with SUVmax<6. The 6-month and 1-year DFS were 
79%  and  40%  for  SUVmax>6  and  80%  and  58%  for  SUVmax<6,  respectively 
(P=0.148, Figure 3).
Excluding patients who underwent neoadjuvant treatment (n=14), median SUVmax 
was 3.3 in patients without recurrence versus 3.8 in those with recurrence (P=NS). In 
this subgroup of patients, median DFS was 10 months for those with SUVmax>6 and 
it was not reached for patients with SUVmax<6. The 6-month and 1-year DFS were  
78%  and  39%  for  SUVmax>6  and  84%  and  65%  for  SUVmax<6,  respectively 
(P=0.076, Figure 4).
Figure 2.  Disease-free survival for the entire cohort of 60 patients who underwent surgical 
resection  for pancreatic cancer. 
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Figure 3.  Disease-free survival for the entire cohort of 60 patients who underwent surgical 
resection  for pancreatic cancer according to SUVmax value < 6 (n=31) and > 6 (n=29). 
Figure  4.  Disease-free  survival  for  resected  patients  excluding  those  who  underwent 
neoadjuvant treatment according to SUVmax value < 6 (n=19)  and > 6 (n=27). 
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DISCUSSION
Preoperative evaluation of the extent of pancreatic adenocarcinoma is crucial in order 
to decide the most appropriate treatment options and to avoid futile laparotomies. In 
recent  years  advances  in  high-resolution  imaging  techniques  have  significantly 
improved  the  quality  of  preoperative  tumor-staging.  MDCT,  eventually  associated 
with other procedures such as endoscopic ultrasound (EUS), can give accurate data 
regarding  the  invasion  of  peripancreatic  structures  (T  stage)  and  thus  “local  
resecability” [8-13,33]. However, the identification of distant metastases may be more 
problematic, especially for small metastatic lesions. In this setting, in 10 to 15% of 
patients deemed to be resectable after conventional imaging staging, surgical resection 
cannot be performed because of locally advanced tumors or occult metastatic disease 
[8-14,]. Another 20% of patient who undergo resection will develop tumor recurrence 
and die of disease within 12 months after surgery [2,5]. These “early recurrences” can 
be  attributed  to  occult  metastatic  disease.  Better  diagnostic  tools  are  needed  to 
improve preoperative patient selection in order to offer surgery to those who are likely 
to benefit from it.
(18)F-FDG  PET/CT   has  been  shown  to  be  an  accurate  examination  for  the  
preoperative staging,  identification of occult metastatic disease and of early tumor-
recurrence,  and  evaluation  of  treatment  response  in  different  tumors  [14-22]. 
Nowadays PET/CT imaging is a standard practice in staging of lung and esophageal  
carcinoma [15,16].
On the other hand, the role of (18)F-FDG PET/CT  in the management of pancreatic 
cancer  patients  is  controversial.  While  some  authors  have  reported  a  significant 
clinical impact of this technique in the staging of patients with resectable pancreatic  
cancer, others showed a limited value, even in the detection of metastases [23-29].
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In  this  prospective  study  we  demonstrated  that  whole  body  (18)F-FDG  PET/CT 
significantly improves patients selection by changing the oncological management of 
25%  of  a  cohort  of  patients  with  resectable  pancreatic  cancer.  Farma  et  al.  and 
Heinrich et al. showed that PET/CT modified the management of 11% and 16% of 
their patients, respectively, with a specific focus on the differentiation between benign 
and malignant pancreatic tumors and preoperative staging [12,23]. The 25% rate of  
our  study  is  particularly  high,  considering  that  all  these  patients  underwent 
preoperative high-resolution imaging.  In  our  experience,  patients  management  was 
modified  not  only  because  of  the  detection  of  occult  metastases  but  also  for  the 
identification of synchronous extra-pancreatic tumors or lymph node metastases that 
required an extension of the lymphadenectomy at laparotomy. 
Of  note,  if  we do  not  consider  patients  who underwent  (18)F-FDG PET/CT after 
neoadjuvant treatment and characterized by a SUVmax < 3 in most cases, the impact 
of this diagnostic technique on patients management rises from 25 to 31%. Nineteen 
per  cent  of  the  72  patients  included  in  this  study  underwent  neoadjuvant 
chemotherapy/chemoradiation  for  a  locally-advanced  or  borderline  resectable 
pancreatic cancer. Neoadjuvant treatment was significantly associated with the lack of  
an  increased  FDG  uptake  at  PET/CT  (SUVmax  <  3).  Therefore  neoadjuvant 
chemotherapy/chemoradiation  induces  a  decrease  of  FDG  uptake  capability  by 
tumors. These finding are confirmed by other studies. Kittada and colleagues, in a 
cohort  of  40 patients  with locally  advanced pancreatic  cancer,  found a  significant  
decrease  of  median  SUVmax  value  from  4.7  to  2.2  after  chemoradiation  [34].  
Similarly Topkan et al. reported a significant SUVmax decrease after chemoradiation 
(from a 14.5 to 3.9,  pre and postchemoradiation median values) [35].  Recent  data 
suggest that a reduction > 50% in FDG uptake after neoadjuvant treatment compared 
to baseline values is associated with better treatment response and improved clinical 
outcomes  [34-36].  Therefore,   in  patients  who  undergo  neoadjuvant  therapy  it  is 
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mandatory to perform a pre-treatment, baseline evaluation with PET/CT in order to 
evaluate a “metabolic treatment response”.
In this study  (18)F-FDG PET/CT excluded from surgical exploration 11% of patients 
scheduled for laparotomy because of the presence of metastatic disease. Sensitivity 
and specificity of PET/CT for the identification of metastases were 78 and 100%, 
respectively, and remarkably sensitivity rate was 87.5% considering patients who did 
not undergo neoadjuvant treatment. In previous series, sensitivity of PET/CT for the  
diagnosis of metastatic disease ranged between 68 and 91%, while specificity was in 
between 64 and 95% [23-26,36-40]. Frohlich and colleagues showed that sensitivity of 
(18)F-FDG PET/CT in detecting liver metastases was 97% for lesions greater than 1 
cm in size but it was only 43% if the size was less than 1 cm, underlying that even for 
PET/CT tumor size is an important parameter [40]. On the other hand the diagnosis of 
peritoneal  metastases  can  be  problematic.  Diederisch  et  al.  Reported  a  PET/CT 
sensitivity of only 25% for the detection of peritoneal disease [37]. More recently a  
study  by  Panagiotidis  E  et  al.  indicated  a  high  incidence  of  peritoneal  implants  
revealed by (18)F-FDG PET/CT in a number of malignancies including pancreatic 
cancer, with an overall accuracy of 91% [41]. 
Since  PET/CT  is  an  expensive  diagnostic  tool,  the  identification  of  subgroup  of 
patients that may benefit from PET/CT after conventional staging work-up could be of 
clinical interest. It has been suggested that serum perioperative CA 19.9 levels can  
correlate  with  tumor  burden  and  tumor  spread  in  resectable  pancreatic  cancer.  A 
preoperative CA 19.9 level > 200 U/mL is associated with early recurrence and poor 
survival after pancreatectomy for pancreatic cancer [5,42]. In the present study we 
found  that  median  CA  19.9  level  was  higher  in  patients  with  metastatic  disease  
showed  at  PET/CT  (292  versus  49  U/mL).  The  difference  was  not  statistically 
significant  likely because  of  the  low number  of  metastatic  patients.  However,  the 
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performance of (18)F-FDG PET/CT should be highly recommended in patients with 
resectable pancreatic cancer at high resolution imaging but with CA 19.9 > 200 U/mL.
In our experience (18)F-FDG PET/CT was poorly sensitive for the detection of lymph 
node metastases. In fact sensitivity and specificity for nodal involvement were 21 and  
93%, respectively. These data are in keeping with the current literature [23-26,36-40]. 
There are several possible causes that may explain these disappointing results. Firstly,  
pancreatic cancer is commonly associated with a high rate of lymph node metastases 
(70/80%) [2,3]. Secondly, most metastatic nodes are in the peripancreatic tissue, close 
to the primary tumor. Thirdly, metastatic nodes are commonly small in size (diameter 
<  1  cm).  Based  on  these  findings,  (18)F-FDG  PET/CT  poorly  sensitive  in 
distinguishing  between primary  pancreatic  cancer  and its  peripancreatic  metastatic 
nodes. An interesting and new finding from our study is the capability of (18)F-FDG 
PET/CT to identify lymph node metastases in nodal stations that are not comprised in 
the area of standard lymphadenectomy. In eight  of  the 61 resected patients (13%) 
lymphadenectomy  was  extended  to  lymph  nodes  along  the  superior  mesenterica 
artery,  celiac  trunk  and  to  para-aortic  nodes.  Nodal  metastases  were  found  at 
histological  examination  in  seven of  these  eight  patients  (87.5%).  Para-aortic  and 
celiac trunk lymph node metastases are associated with poor prognosis in pancreatic 
cancer [43,44]. The preoperative identification of nodal metastases at these sites could 
represent an indication for neoadjuvant treatment, but accurate preoperative diagnosis 
is difficult [45]. In this light (18)F-FDG PET/CT, characterized by a high specificity 
for nodal metastases, may represent a new diagnostic tool for the proper identification  
of these patients that should be considered for neoadjuvant chemotherapy instead of 
upfront surgery.
We aimed to evaluate a possible correlation between preoperative SUVmax values 
and  tumor-recurrence.  Okamoto  et  al.  in  a  series  of  56  patients  who  underwent 
pancreatic  resection for  pancreatic  cancer,  showed that  preoperative SUVmax was 
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significantly higher in patients who experienced tumor –recurrence, and that SUVmax 
was the only independent  predictor of  early recurrence [29].  However,  our results 
failed to demonstrate a significant difference in SUVmax values among patients with 
and without recurrence. One-year DFS was better for patients with SUVmax < 6 but 
the difference was not statistically significant (P=0.148) likely because the relatively 
short  follow  up  time  of  this  cohort.  Of  note,  excluding  patients  who  underwent 
neoadjuvant therapy, the DFS difference between patients with SUVmax > and < 6 
improved, but again without reaching significance (P=0.076). An ultimate conclusion 
regarding the correlation between SUVmax and DFS cannot be drawn. Therefore a 
longer follow-up is needed to obtain definitive results.
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CONCLUSIONS
(18)FDG-PET/CT findings resulted in changes of therapeutic management/operative 
procedures in one third of patients.  (18)FDG-PET/CT improves staging of patients 
with resectable pancreatic cancer, particularly for the detection of occult metastatic 
disease. Although (18)FDG-PET/CT has limited value in characterizing the N status, 
it was helpful to detect loco-regional nodal metastases that required an extension of  
the  lymphadenectomy  or  a  neoadjuvant  treatment.  Neoadjuvant  treatment  is 
significantly associated with low metabolic activity limiting the value of (18)FDG-
PET/CT in  this  setting.  Longer  follow-up  data  are  needed  to  evaluate  a  possible 
correlation  between  SUVmax  and  disease-free  survival.  Based  on  these  results,  
(18)FDG-PET/CT should be considered as part of the preoperative staging of patients 
with resectable pancreatic cancer after  high-resolution imaging,  especially in those 
with high CA 19.9 serum levels.
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